Sökning: onr:"swepub:oai:lup.lub.lu.se:ad34a9da-47ba-436c-87aa-98a17a7a1685" >
Tamoxifen and contr...
Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update
- Artikel/kapitelEngelska2006
Förlag, utgivningsår, omfång ...
Nummerbeteckningar
-
LIBRIS-ID:oai:lup.lub.lu.se:ad34a9da-47ba-436c-87aa-98a17a7a1685
-
https://lup.lub.lu.se/record/414468URI
-
https://doi.org/10.1002/ijc.21536DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:art swepub-publicationtype
-
Ämneskategori:ref swepub-contenttype
Anmärkningar
-
Women with a mutation in BRCA1 or BRCA2 face a lifetime risk of breast cancer of similar to 80%, and following the first diagnosis the 10-year risk of contralateral breast cancer is similar to 30%. It has been shown that both tamoxifen and oophorectomy prevent contralateral breast cancer, but it is not clear whether there is a benefit in giving tamoxifen to women who have previously undergone an oophorectomy. Furthermore, the relative degree of protection in BRCA1 and BRCA2 carriers has not been well evaluated. We studied 285 women with bilateral breast cancer and a BRCA1 or BRCA2 mutation, and 751 control women with unilateral breast cancer and a BRCA1 or BRCA2 mutation in a matched case-control study. Control women were of similar age and had a similar age of diagnosis of breast cancer and had been followed for as long as the case for a second primary breast cancer. The history of tamoxifen use for treating the first breast cancer was compared between bilateral and unilateral cases. The multivariate odds ratio for contralateral breast cancer associated with tamoxifen use was 0.50 for carriers of BRCA1 mutations (95% CI, 0.304.85) and was 0.42 for carriers of BRCA2 mutations (95% CI, 0.17-1.02). The protective effect of tamoxifen was not seen among women who had undergone an oophorectomy (OR = 0.83; 95% CI, 0.242.89) but this subgroup was small. In contrast, a strong protective effect of tamoxifen was apparent among women who were premenopausal or who had undergone natural menopause (OR = 0.44; 95% CI, 0.27-0.65). (c) 2005 Wiley-Liss, Inc.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Tung, N
(författare)
-
Foulkes, WD
(författare)
-
Offit, K
(författare)
-
Gershoni, R
(författare)
-
Daly, M
(författare)
-
Kim-Sing, C
(författare)
-
Olsson, HåkanLund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine(Swepub:lu)onk-hol
(författare)
-
Ainsworth, P
(författare)
-
Eisen, A
(författare)
-
Saal, H
(författare)
-
Friedman, E
(författare)
-
Olopade, O
(författare)
-
Osborne, M
(författare)
-
Weitzel, J
(författare)
-
Lynch, H
(författare)
-
Ghadirian, P
(författare)
-
Lubinski, J
(författare)
-
Sun, P
(författare)
-
Narod, SA
(författare)
-
Bröstcancer-genetikSektion I
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:International Journal of Cancer: Wiley118:9, s. 2281-22840020-71361097-0215
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Gronwald, J
-
Tung, N
-
Foulkes, WD
-
Offit, K
-
Gershoni, R
-
Daly, M
-
visa fler...
-
Kim-Sing, C
-
Olsson, Håkan
-
Ainsworth, P
-
Eisen, A
-
Saal, H
-
Friedman, E
-
Olopade, O
-
Osborne, M
-
Weitzel, J
-
Lynch, H
-
Ghadirian, P
-
Lubinski, J
-
Sun, P
-
Narod, SA
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
International Jo ...
- Av lärosätet
-
Lunds universitet